StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH)

StockNews.com began coverage on shares of Bio-Path (NASDAQ:BPTH) in a research report released on Tuesday morning. The brokerage issued a sell rating on the stock.

Bio-Path Price Performance

Shares of Bio-Path stock opened at $0.17 on Tuesday. Bio-Path has a one year low of $0.12 and a one year high of $7.67. The business has a 50-day simple moving average of $0.51 and a 200-day simple moving average of $0.80.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.